Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol
; 8(4): 343-355, 2023 04.
Article
in En
| MEDLINE
| ID: mdl-36736339
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Crohn Disease
Type of study:
Clinical_trials
/
Guideline
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
Lancet Gastroenterol Hepatol
Year:
2023
Document type:
Article
Affiliation country: